Southern Shuanglin shareholders approve governance revisions

Southern Shuanglin Bio-Pharmacy (SZSE:000403) announced the successful conclusion of its 2025 fourth extraordinary general meeting of shareholders, where all proposed resolutions regarding governance amendments were passed without opposition. The meeting was held on December 22, 2025, with both on-site and online participation. A total of 363 shareholders, representing 36.0176% of the total voting shares, attended.

The primary agenda item, "Proposals on Amending the Articles of Association and Certain Governance Systems," was approved with a significant majority. For instance, the amendment to the "Articles of Association" passed with 338,524,367 votes in favor (98.8940%), 3,737,691 votes against (1.0919%), and 48,430 abstentions (0.0141%).

Other approved proposals included amendments to the "Rules of Procedure for Shareholder Meetings," "Rules of Procedure for Board Meetings," "Management System for Raised Funds," "Independent Director Work System," "External Guarantees Management System," "Major Investment Management System," "Connected Transaction Management System," and "Remuneration Management System for Directors and Senior Management." Lawyers from Beijing Jiayuan Law Firm confirmed the legality and validity of the proceedings and results.